Prescribing of glucose‐lowering medication to adults with type 2 diabetes by severe mental illness status in Scotland: A cohort study
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70278 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Jilly Adams und 7 weiteren Autor:innen. Beteiligte Einrichtung: Usher Institute, University of Edinburgh, Edinburgh, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Mental Disorders, Practice Patterns, Physicians'. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI, UK Research and Innovation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
We aimed to determine whether glucose‐lowering medication (GLM) prescribing differs by severe mental illness (SMI) status. Materials and methods We conducted a population‐based cohort study using routinely collected linked data, including people in Scotland diagnosed with type 2 diabetes between January 2004 and March 2022. We used Cox proportional hazards models to compare the time from diabetes diagnosis to the first prescription of each of metformin and insulin in people with and without a hospital admission record of SMI (schizophrenia, bipolar disorder or depression prior to diabetes diagnosis). We adjusted for age, sex, area‐based socio‐economic deprivation, smoking status and baseline HbA1c and estimated glomerular filtration rate.
Results
Among 317 761 people with type 2 diabetes, 14 600 (4.6%) had pre‐existing SMI. During a median follow‐up of 1.6 years, 10 859 (74%) of those with SMI and 219 823 (73%) without SMI were prescribed metformin. After accounting for confounders, people with SMI received their first metformin (HR 1.09, 95% CI: 1.07–1.11) and insulin (HR 1.24, 95% CI: 1.18–1.31) prescriptions at a faster rate than people without SMI. Body mass index (BMI) was missing in 21% of participants, but similar estimates were obtained when we additionally adjusted for BMI in analyses that only included people with BMI data.
Conclusions
Among people with type 2 diabetes each of metformin and insulin is prescribed sooner in people with compared to those without SMI. Further research is needed to understand the reasons for this, and to investigate the implications of these differences in prescribing patterns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Usher Institute, University of Edinburgh, Edinburgh, UK.
- MRC Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
ORCID-Profile: Caroline A Jackson
Förderung
- UKRI
- UK Research and Innovation
Zitieren
APA
Adams, J., Saha, S., Fleetwood, K. J., Blackbourn, L. A. K., McGurnaghan, S. J., Wild, S. H., Jackson, C. A., & Scottish Diabetes Research Network Epidemiology Group (2026). Prescribing of glucose‐lowering medication to adults with type 2 diabetes by severe mental illness status in Scotland: A cohort study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70278
Vancouver
Adams J, Saha S, Fleetwood KJ, Blackbourn LAK, McGurnaghan SJ, Wild SH, et al. Prescribing of glucose‐lowering medication to adults with type 2 diabetes by severe mental illness status in Scotland: A cohort study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70278
BibTeX
@article{Adams2026,
author = {Adams, Jilly and Saha, Shuvajit and Fleetwood, Kelly J and Blackbourn, Luke A K and McGurnaghan, Stuart J and Wild, Sarah H and Jackson, Caroline A and Scottish Diabetes Research Network Epidemiology Group, Scottish Diabetes Research Network Epidemiology Group},
title = {Prescribing of glucose‐lowering medication to adults with type 2 diabetes by severe mental illness status in Scotland: A cohort study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70278}
}
EUVIMED